MELK and adrenal cortex carcinoma: In this study, the combination of the maternal embryonic leucine zipper kinase (MELK) inhibitor (OTS167) and the cyclin-dependent kinase (CDK) inhibitor (RGB-286638) was identified as a novel treatment in ACC.